ProQuad

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
22-07-2022
Ciri produk Ciri produk (SPC)
22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
08-10-2020

Bahan aktif:

virus, live attenuated, measles, virus, live attenuated, mumps, virus, live attenuated, rubella, virus, live attenuated, varicella

Boleh didapati daripada:

Merck Sharp & Dohme B.V.

Kod ATC:

J07BD54

INN (Nama Antarabangsa):

measles, mumps, rubella and varicella vaccine (live)

Kumpulan terapeutik:

Vaccines

Kawasan terapeutik:

Chickenpox; Rubella; Measles; Mumps; Immunization

Tanda-tanda terapeutik:

ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age. ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles.,

Ringkasan produk:

Revision: 31

Status kebenaran:

Authorised

Tarikh kebenaran:

2006-04-05

Risalah maklumat

                                38
B. PACKAGE LEAFLET
39
PACKAGE LE
AFLET: INFORMATION FOR THE USER
PROQUAD
POWDER AND SO
LVENT FOR SUSPENSION FOR INJECTION
Measles, mumps, rubella and varicella vac
cine (live)
R
EAD ALL OF THIS LEAFLE
T CAREFULLY BEFORE YOU OR YO
UR CHILD IS VACCINA
TED
BECAUSE IT CONTAINS
IMPORTANT INFORMATI
ON FOR YOU.
-
Keep this leaflet. You may ne
ed to read it again.
-
If you have any further questions, ask your doctor or your pharm
acist.
-
This
vaccine has been presc
ribed for you o
r your child
only. Do not pass i
t on to others.
-
If you get any of the sid
e effects, talk to your doctor or pharmacis
t. This inc
ludes any possible
side effects not listed in this leaflet.
See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pro
Quad is and wha
t it is used for
2.
What you need
to know before you receive ProQuad
3.
How
to use ProQuad
4.
Possible side effects
5.
How to store ProQuad
6.
Contents of the pack and other information
1.
WHAT PROQUAD I
S AND WHAT IT IS USED FOR
ProQuad
is a vaccine co
ntaining meas
les, mumps, rubella,
and chickenpox (varicella) viruses that
h
ave been weakened. When
a person is
given the vaccine, the immune system (the body’s natural
defences
) will make antibodies agains
t the measles,
mumps, rubella, and
varicella viruses. The
antibo
dies help protect against diseases caused by these viruses.
P
roQuad is given to help
protect you
r child against measles, mumps, rubella
, and chickenpox
(varicella)
. The vaccine may be adminis
tered to perso
ns from 12 months of
age.
ProQuad ma
y also be adm
inistered to infants from 9 months of age under special circum
stances (to
co
nform with national vaccination schedules, outbreak situatio
ns, or travel to a
region with high
prevalence of measle
s).
Although
ProQuad contains liv
e
viruses, they a
re too weak t
o cause measles, mumps, rubella, or
chickenpox (varicella) in
healthy people.
2.
WHAT YOU NEED TO KNOW BEFORE YOU
RECEIVE PROQUAD
DO
NOT USE PROQUAD

If the person to be vaccinated is aller
gic to any varicella
vaccine or mea
sles, mumps, or rubella
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY
OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ProQuad powder and solvent for suspension for injection
ProQuad powder and solvent for suspension for
injection in a pre-filled syringe
Measles, mump
s,
rubella and varicella vaccin
e (live).
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
After reconstitution, one dose (0.5
mL) contains:
Measles virus
1
Enders’ Edmonston strain (live, attenuated)
........ not less than 3.00 log
10
TCID
50
*
Mumps virus
1
Jeryl Lynn
™
(Le
vel B) strain (live, attenua
ted) ...
not less than 4.30 log
10
TCID
50
*
Rubella virus
2
Wistar RA 27/3 strain (live, attenuated)
...............
not less than 3.00 log
10
TCID
50
*
Varicella virus
3
Oka/Merck strain (live, attenuat
ed) ...................
not less than 3.99 log
10
PFU**
*50% tissue cultur
e infectious dose
**plaque-f
orming units
(
1
) Produced in chick embryo cells.
(
2
) Produced in human diploid lung (WI
-38) fibroblasts.
(
3
) Produced in human diploid (MRC
-5) cells.
The vaccine may contain
traces of recombinant human alb
umin (rHA).
This vacc
ine contains a trace amount
of neomycin. See section 4.3.
Excipient(s)
with known effect
The vaccine contains 16
milligrams
of sorbitol per dose.
See section 4.4.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder and solve
nt for suspension for injection
Before r
econstitution, the pow
der is a white to pale yellow
compact
crystalline cake and the solvent is
a clear colourless liquid.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
ProQuad is indicated for simultaneous
vaccination against measles, mumps, rub
ella and varicella in
individuals from 12
months of age.
ProQuad
can be administered to individuals from 9
months of
age under special circumstances (e.g.,
to conform with national vaccination sche
dules, outbreak
situations, or travel to a region with hig
h
prevalence of measle
s; see sections 4.2, 4.4, and
5.1).
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
ProQu
ad should be used in accordance to official r
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 22-07-2022
Ciri produk Ciri produk Bulgaria 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 08-10-2020
Risalah maklumat Risalah maklumat Sepanyol 22-07-2022
Ciri produk Ciri produk Sepanyol 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 08-10-2020
Risalah maklumat Risalah maklumat Czech 22-07-2022
Ciri produk Ciri produk Czech 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Czech 08-10-2020
Risalah maklumat Risalah maklumat Denmark 22-07-2022
Ciri produk Ciri produk Denmark 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 08-10-2020
Risalah maklumat Risalah maklumat Jerman 22-07-2022
Ciri produk Ciri produk Jerman 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 08-10-2020
Risalah maklumat Risalah maklumat Estonia 22-07-2022
Ciri produk Ciri produk Estonia 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 08-10-2020
Risalah maklumat Risalah maklumat Greek 22-07-2022
Ciri produk Ciri produk Greek 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Greek 08-10-2020
Risalah maklumat Risalah maklumat Perancis 22-07-2022
Ciri produk Ciri produk Perancis 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 08-10-2020
Risalah maklumat Risalah maklumat Itali 22-07-2022
Ciri produk Ciri produk Itali 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Itali 08-10-2020
Risalah maklumat Risalah maklumat Latvia 22-07-2022
Ciri produk Ciri produk Latvia 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 08-10-2020
Risalah maklumat Risalah maklumat Lithuania 22-07-2022
Ciri produk Ciri produk Lithuania 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 08-10-2020
Risalah maklumat Risalah maklumat Hungary 22-07-2022
Ciri produk Ciri produk Hungary 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 08-10-2020
Risalah maklumat Risalah maklumat Malta 22-07-2022
Ciri produk Ciri produk Malta 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Malta 08-10-2020
Risalah maklumat Risalah maklumat Belanda 22-07-2022
Ciri produk Ciri produk Belanda 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 08-10-2020
Risalah maklumat Risalah maklumat Poland 22-07-2022
Ciri produk Ciri produk Poland 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Poland 08-10-2020
Risalah maklumat Risalah maklumat Portugis 22-07-2022
Ciri produk Ciri produk Portugis 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 08-10-2020
Risalah maklumat Risalah maklumat Romania 22-07-2022
Ciri produk Ciri produk Romania 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Romania 08-10-2020
Risalah maklumat Risalah maklumat Slovak 22-07-2022
Ciri produk Ciri produk Slovak 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 08-10-2020
Risalah maklumat Risalah maklumat Slovenia 22-07-2022
Ciri produk Ciri produk Slovenia 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 08-10-2020
Risalah maklumat Risalah maklumat Finland 22-07-2022
Ciri produk Ciri produk Finland 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Finland 08-10-2020
Risalah maklumat Risalah maklumat Sweden 22-07-2022
Ciri produk Ciri produk Sweden 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 08-10-2020
Risalah maklumat Risalah maklumat Norway 22-07-2022
Ciri produk Ciri produk Norway 22-07-2022
Risalah maklumat Risalah maklumat Iceland 22-07-2022
Ciri produk Ciri produk Iceland 22-07-2022
Risalah maklumat Risalah maklumat Croat 22-07-2022
Ciri produk Ciri produk Croat 22-07-2022
Laporan Penilaian Awam Laporan Penilaian Awam Croat 08-10-2020

Lihat sejarah dokumen